Cytek Biosciences Inc
CTKB4.620USD
+0.080+1.76%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
590.74MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cytek Biosciences Inc Unternehmen
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Cytek Biosciences Inc Informationen
BörsenkürzelCTKB
Name des UnternehmensCytek Biosciences Inc
IPO-datumJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Anzahl der mitarbeiter648
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
Addresse47215 Lakeview Boulevard
StadtFREMONT
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94538
Telefon18779229835
Websitehttps://cytekbio.com
BörsenkürzelCTKB
IPO-datumJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Führungskräfte von Cytek Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
10.18K
+27.27%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
Nach RegionUSD
Name
Umsatz
Anteil
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
Aktionärsstatistik
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
Andere
68.45%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
Andere
68.45%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
20.84%
Individual Investor
9.28%
Hedge Fund
7.26%
Pension Fund
1.17%
Research Firm
1.00%
Bank and Trust
0.37%
Family Office
0.11%
Venture Capital
0.09%
Andere
30.76%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
315
75.48M
59.03%
-10.81M
2025Q2
324
88.51M
69.57%
-10.34M
2025Q1
332
90.47M
71.35%
-13.48M
2024Q4
323
90.06M
70.25%
-11.48M
2024Q3
303
87.47M
66.52%
-16.26M
2024Q2
288
88.67M
67.45%
-13.39M
2024Q1
284
98.75M
75.24%
-12.70M
2023Q4
276
96.90M
74.11%
-15.57M
2023Q3
266
97.16M
71.81%
-17.75M
2023Q2
259
98.92M
72.71%
-3.90M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.73M
2.15%
+42.92K
+1.60%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Invesco S&P SmallCap Health Care ETF
0.24%
Royce Quant Small-Cap Quality Value ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
iShares S&P Small-Cap 600 Value ETF
0.05%
SPDR S&P 600 Small Cap Value ETF
0.05%
Principal U.S. Small-Cap ETF
0.04%
iShares Biotechnology ETF
0.04%
Proshares Ultra Smallcap 600
0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.03%
Mehr Anzeigen
Invesco S&P SmallCap Health Care ETF
Anteil0.24%
Royce Quant Small-Cap Quality Value ETF
Anteil0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.06%
Avantis US Small Cap Equity ETF
Anteil0.05%
iShares S&P Small-Cap 600 Value ETF
Anteil0.05%
SPDR S&P 600 Small Cap Value ETF
Anteil0.05%
Principal U.S. Small-Cap ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
Proshares Ultra Smallcap 600
Anteil0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Anteil0.03%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
